DS
RAPT

David Shaw’s RAPT Therapeutics RAPT Stock Holding History

David Shaw’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,490
Closed -$102K – 4657
2025
Q1 		$102K Sell
10,490
-85,762
-89% -$843K ﹤0.01% 4015
2024
Q4 		$1.22M Sell
96,252
-34,771
-27% -$442K ﹤0.01% 3094
2024
Q3 		$2.11M Buy
131,023
+17,596
+16% +$356K ﹤0.01% 2672
2024
Q2 		$2.77M Buy
113,427
+79,659
+236% +$3.68M ﹤0.01% 2333
2024
Q1 		$2.43M Buy
+33,768
New +$4.69M ﹤0.01% 2479
2023
Q3 		– Sell
-2,142
Closed -$320K – 4441
2023
Q2 		$320K Sell
2,142
-9,866
-82% -$1.54M ﹤0.01% 3581
2023
Q1 		$1.76M Sell
12,008
-3,830
-24% -$775K ﹤0.01% 2780
2022
Q4 		$2.51M Buy
15,838
+3,403
+27% +$545K ﹤0.01% 2742
2022
Q3 		$2.39M Buy
+12,435
New +$2.35M ﹤0.01% 2841
2022
Q1 		– Sell
-8,581
Closed -$2.52M – 5861
2021
Q4 		$2.52M Sell
8,581
-7,390
-46% -$1.98M ﹤0.01% 3136
2021
Q3 		$3.97M Buy
15,971
+9,986
+167% +$2.64M ﹤0.01% 2342
2021
Q2 		$1.52M Buy
+5,985
New +$1.12M ﹤0.01% 3197

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

David Shaw's RAPT Position: Q2 2025 in Review

David Shaw sold out of RAPT Therapeutics (RAPT) in Q2 2025, closing a stake of 10,490 shares — an estimated $102K sold.

David Shaw first reported a position in RAPT in Q2 2021 and held it in 12 quarters. The position peaked at $3.97M in Q3 2021. 50 funds tracked by Wall St. Rank hold RAPT as of Q2 2025.

  • David Shaw reported no remaining RAPT Therapeutics position as of Q2 2025 after selling out during the quarter.
  • David Shaw sold 10,490 RAPT Therapeutics shares in Q2 2025, an estimated $102K.
  • David Shaw first reported a position in RAPT Therapeutics in Q2 2021 and held it in 12 quarters.
  • David Shaw's RAPT Therapeutics position peaked at $3.97M in Q3 2021.
  • 50 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.